Misdiagnoses of multiple sclerosis (MS) represent one of the prominent challenges in MS for patients, clinicians, and researchers. A variety of factors influence misdiagnosis, including testing deficiencies, copycat diseases, and more.
Horizon Therapeutics plc: New Analysis of UPLIZNA (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
published in the
Annals of Neurology assesses a potential new biomarker for NMOSD attack risk, severity and treatment effects
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis of the pivotal Phase 2/3 N-MOmentum trial for UPLIZNA (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with NMOSD. These data are published in the May issue of
Neurology Neuroimmunology Neuroinflammation. UPLIZNA is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Certain DMTs in MS May Attenuate COVID-19 Vaccines medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.